|
Chemical
Name:
Thioxhixene hydrochloride Brand
Name:
Navane
Manufacturer:
Pfizer,
Inc. Description:
Thioxanthene that probably blocks postsynaptic
dopamine receptors in the brain. Indications
and Use: For
the management of the manifestations of psychotic disorders. Contraindications,
Warnings and Precautions:
Contraindicated
in patients with circulatory collapse, comatose states, central nervous system
depression and blood dyscrasias. The
potentially fatal symptom complex of Neuroleptic Malignant Syndrome (NMS) has
been reported in association with this class of drugs.
Signs of NMS include muscle rigidity, altered mental status, high fever,
increased blood pressure, increased heart rate and cardiac dysrhythmia.
Tardive Dyskinisia (TD) is a potentially irreversible, involuntary
movement that may develop. The highest prevalence of TD is in the elderly, particularly
women. Navane may mask signs of
overdosage of toxic drugs and may obscure conditions such as intestinal
obstruction and brain tumor because of its antiemetic effect.
Use with extreme caution in patients with a history of convulsive
disorder, since Navane may lower the seizure threshold.
Use with caution in patients with cardiovascular disease. Adverse
Reactions:
Possible common side effects may include extrapyramidal reactions,
hypotension, blurred vision, dry mouth, constipation, urinary retention and mild
photosensitivity. Other side effects may include drowsiness, restlessness,
agitation, insomnia, dizziness, ECG changes, nasal congestion, menstrual
irregularities and leukocytosis. Dosing
Range:
Individually adjusted according to the chronicity and severity of the
condition. The usual optimal dose
is 20 to 30mg per day. |
|
These pages are solely for public informational purposes. The information cannot be relied on to make diagnoses or prescribe treatment in any individual. Persons who require such services should consult with a licensed professional. Send mail to ropa@redoakpsychiatry.com with questions or comments about this web site.© 2000 Red Oak Psychiatry Associates, P.A. Updated
11/26/2007
|